Hepatology (Baltimore, Md.)
August 4, 2026 · via Europe PMC
Hepatocyte MLKL drives obesity-driven hepatocellular carcinoma progression via mitochondrial dysfunction independent of necroptosis in MASLD.
Ohene-Marfo P, Mohammed S, Jiang C, +18 more, Deepa SS.
AI summary — for doctors, generated from the abstract only
A mouse study found that the protein MLKL, normally known for driving cell-death signaling, promotes obesity-related liver cancer through a different, non-cell-death mechanism involving mitochondrial dysfunction, and that deleting or inhibiting it reduced tumor development, suggesting MLKL as a potential new drug target.
What was studied
A preclinical study using hepatocyte-specific MLKL knockout mice in a long-term western diet-induced model of obesity-related MASLD-associated hepatocellular carcinoma, combined with cell culture experiments and human tumor correlation, to determine MLKL's role in tumor development independent of its classical function in necroptosis (a form of programmed cell death).
Key findings
- Western diet feeding increased hepatocyte MLKL protein expression without activating necroptosis, indicating MLKL was acting through a necroptosis-independent mechanism; MLKL deficiency did not change diet-induced inflammation, fibrosis, or liver injury but increased lipid accumulation while reducing toxic lipid species and preserving mitochondrial function.
- Western-diet-fed mice lacking hepatocyte MLKL developed fewer and smaller tumors, with reduced tumor incidence, multiplicity, proliferation, and stemness, associated with restored expression of the mitochondrial fusion protein/tumor suppressor MFN2 and increased mitochondrial oxidative phosphorylation gene expression.
- In human HCC cells, deleting MLKL reduced proliferation and improved mitochondrial function (effects reversed by also deleting MFN2); a human MLKL inhibitor (necrosulfonamide) suppressed tumor growth in a xenograft model, and higher MLKL expression in human HCC tumors correlated with worse overall survival.
Clinical relevance
The findings suggest MLKL could be a potential therapeutic target for obesity-related liver cancer through a mitochondrial mechanism distinct from its known role in cell death, and that MLKL expression might eventually serve as a prognostic marker, but this is preclinical mouse and cell-line research and would require substantial further study before any clinical application.
Who should care
Limitations
Important limitations may not be assessable from the abstract alone; this is a preclinical mouse and cell-line study, with human correlation limited to a survival association rather than interventional data.
A mouse study found the protein MLKL drives obesity-related liver cancer through a mitochondrial mechanism separate from its known cell-death role, and that blocking it reduced tumor growth, pointing to a possible new drug target.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Background and aims
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of HCC, particularly in obesity, yet mechanisms linking hepatocyte dysfunction to tumorigenesis remain unclear. Mixed lineage kinase domain-like protein (MLKL), the effector of necroptosis, is elevated in MASLD, but its hepatocyte-intrinsic role in obesity-driven MASLD-HCC is unknown.
Approach and results
Using a long-term western diet (WD)-induced MASLD-HCC model in hepatocyte-specific MLKL knockout ( MlklHepKO ) mice, we defined MLKL's hepatocyte-intrinsic function. WD increased hepatocyte MLKL protein expression without detectable necroptosis activation, indicating a necroptosis-independent role. MLKL deficiency did not alter WD-induced inflammation, fibrosis, or liver injury but increased hepatic lipid accumulation while reducing lipotoxic lipid species and preserving mitochondrial function. WD-fed MlklHepKO mice developed fewer and smaller tumors with reduced incidence, multiplicity, proliferation, and stemness. Transcriptomic analysis revealed upregulation of mitochondrial oxidative phosphorylation pathways in MlklHepKO livers. WD suppressed the mitochondrial fusion protein and tumor suppressor mitofusin 2 (MFN2), whereas MLKL deficiency restored MFN2 expression post-translationally. In HCC cells, MLKL deletion reduced proliferation, improved mitochondrial respiration, and decreased glycolysis; these effects were reversed by MFN2 deletion. MLKL is localized to nuclear and mitochondrial compartments, consistent with organelle-intrinsic functions. The human MLKL inhibitor necrosulfonamide (NSA) suppressed HepG2 xenograft growth, and elevated MLKL expression in human HCC correlated with poorer overall survival.
Conclusions
Hepatocyte MLKL promotes MASLD-associated HCC through a non-necroptotic mechanism involving MFN2 suppression, impaired mitochondrial function, and increased tumor proliferation and stemness. These findings identify MLKL as a potential therapeutic target in MASLD-associated HCC.
DOI
10.1097/hep.0000000000001830
PMID
42549799
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed